|
WO2020180712A1
|
|
Anti-tnfr2 antibodies and uses thereof
|
|
WO2020061210A1
|
|
Anti-tnfr2 antibodies and uses thereof
|
|
WO2018213747A1
|
|
4-1bb agonist and cd40 agonist bispecific molecules
|
|
WO2018187215A1
|
|
Bispecific 4-1bb agonist molecules
|
|
WO2018160794A1
|
|
Epha2-targeted docetaxel -generating liposomes in combination with an agent that impedes regulatory t cell activity for treating cancer
|
|
WO2018144514A2
|
|
Tnf superfamily fusion polypeptides
|
|
WO2018129451A2
|
|
Anti-fgfr antibodies and methods of use
|
|
WO2018045256A1
|
|
Combination of an erbb3 inhibitor, topoisomerase i inhibitor, and an alkylating agent to treat cancer
|
|
WO2018026942A1
|
|
Heteromeric polypeptides
|
|
US2017314079A1
|
|
Antibodies against epidermal growth factor receptor (egfr) and uses thereof
|
|
AU2017283487A1
|
|
Methods for selecting and treating patients with a trail-based therapeutic or death receptor agonist
|
|
US2017258903A1
|
|
Combination therapies for treating her2-positive cancers that are resistant to her2-targeted therapies
|
|
WO2017172678A1
|
|
Methods for treating cancer using combination therapies comprising an oligoclonal anti-egfr antibody preparation and lipsomal irinotecan
|
|
US2019077870A1
|
|
Engineered trail for cancer therapy
|
|
KR20180121904A
|
|
Ephrin Receptor A2 (EphA2) -donated docetaxel-producing nano-liposome composition
|
|
AU2017232636A1
|
|
Treating ephrin receptor A2 (EphA2) positive cancer with targeted docetaxel-generating nano-liposome compositions
|
|
CN108883199A
|
|
The nano liposomes of ephrins receptor A2 (EPHA2) target and dependent diagnostic
|
|
CN109310754A
|
|
Use the method for conjoint therapy treatment ER+, HER2-, HRG+ breast cancer comprising anti-ERBB3 antibody
|
|
WO2017161009A1
|
|
Dosage and administration of combination therapies comprising targeted antibodies uses and methods of treatment
|
|
WO2017136770A1
|
|
Treatment of her2-intermediate cancer
|
